Medifast (FRA:MDF) YoY EBITDA Growth: -129.49% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MDF Medifast Inc FRA:MDF
63 GF Score
Price €10.36
GF Value €7.24
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Medifast YoY EBITDA Growth?

Medifast FRA:MDF -0.58% 63 YoY EBITDA Growth is -129.49% as of Jun. 2026. GuruFocus rates FRA:MDF with a GF Score™ of 63/100 and a GF Value™ of €7.24 (Significantly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Medifast's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -129.49%.

Medifast's EBITDA per Share for the three months ended in Jun. 2026 was €-0.07.

Medifast YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Medifast's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast YoY EBITDA Growth Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.96 -1.94 -28.52 -88.41 -99.85

Medifast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.21 -111.26 -199.41 -91.23 -129.49
FRA:MDF
63GF Score
Medifast Inc FRA:MDF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Medifast's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.002-1.358)/ | 1.358 |
=-99.85 %

Medifast's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.069-0.234)/ | 0.234 |
=-129.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -129.49% mean?
Medifast (FRA:MDF) has a YoY EBITDA Growth of -129.49% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Medifast and its competitors.
Is Medifast's YoY EBITDA Growth too high?
Medifast's current YoY EBITDA Growth is -129.49%. Overall, Medifast has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's YoY EBITDA Growth compare to RGS and CLIK?
Medifast's YoY EBITDA Growth of -129.49% can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Personal Services company?
A good YoY EBITDA Growth depends on the Personal Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Medifast and its competitors. Medifast's current YoY EBITDA Growth is -129.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (FRA:MDF) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.24, compared to a current price of €10.36 — trading 43.1% above its estimated fair value. The current YoY EBITDA Growth is -129.49%. Medifast's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Medifast (FRA:MDF), the current YoY EBITDA Growth is -129.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medifast (FRA:MDF) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of €10.36 is trading 43.1% above its estimated GF Value™ of €7.24. GuruFocus considers Medifast to be Significantly Overvalued.

Key valuation signals for FRA:MDF:

  • YoY EBITDA Growth: -129.49%
  • GF Value™: €7.24 vs. price of €10.36 (43.1% above fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:MDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medifast Business Description

Other Exchanges MED:USA0K05:UKMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
63GF Score

Get the complete analysis for FRA:MDF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.36
Price
€7.24
GF Value